HiRO Symposium 2024 – Industry Panel Livestream

About this event

The Hearts in Rhythm Organization (HiRO), in partnership with The Canadian SADS Foundation, is proud to present live-streamed industry panel discussions during our annual symposium. This initiative aims to enhance accessibility and engagement by allowing you to participate directly from the comfort of your own space. We are excited to offer patients and families across Canada the opportunity to stay informed about groundbreaking research and emerging therapies for inherited cardiac conditions.

About HiRO:  The Hearts in Rhythm Organization (HiRO; pronounced hero) is a network of individuals dedicated to improving awareness and understanding of inherited cardiac conditions, standardizing care in Canada and preventing the tragedy of sudden cardiac death. Founded by Dr. Andrew Krahn in 2016, HiRO began as a grassroots community of like-minded clinicians wanting to make a difference for Canadians affected by unexplained sudden cardiac arrest (SCA), and has grown into an organization that includes researchers, healthcare providers, family members and patients.

About The Canadian SADS Foundation: Established in 1995, The Canadian Sudden Arrhythmia Death Syndromes (SADS) Foundation, a registered Canadian charity, is the only patient advocacy group in Canada dedicated to supporting patients and families affected by inherited cardiac rhythm disorders. 

This event aims to inform participants about the latest developments involving inherited cardiac conditions. Please note that the inclusion of presentations from pharmaceutical companies during this livestream are intended solely for informational purposes. We do not endorse or recommend any specific therapies discussed. We encourage all attendees to consult with a healthcare professional before considering any new treatment option. 

Introduction to Gene-Based Therapeutics

Gene Therapy: This typically involves introducing genetic material into a patient’s cells to treat or prevent disease. For instance, this approach can replace a faulty gene with a healthy one, add a new gene to help fight a disease, or inactivate a gene that is functioning improperly.

 

Gene Editing: Is a technique that involves directly modifying the DNA within a patients cells. Using tools like CRISPR, specific sequences of DNA can be cut and replaced or repaired, allowing for targeted corrections at the molecular level. Unlike gene therapy, which generally introduces new genetic material, gene editing alters the existing genes to correct mutations directly.

Introduction to Small Molecule Therapies

Small Molecules: Small molecule drugs are chemical substances that can enter cells easily because of their small size. They work by specifically targeting and altering the activity of certain cellular processes. Their mechanism of action is not on the DNA itself but on the products or processes influenced by the DNA.

Have Questions?

Curious about the latest in gene therapies or small molecule treatments for inherited cardiac conditions? Click the button below to submit your questions through our intake form. Our moderation team will review all submissions, and we’ll strive to address your queries during the live moderated discussions.

Livestream Agenda

Overview of Gene-Based Therapeutics (10:00AM - 10:30AM)

Speaker

Session Summary

In this session, Dr. Jason Roberts will provide an accessible introduction to gene-based therapeutics, focusing on their application in treating inherited cardiac conditions.

Session 1: Gene Therapies for Inherited Cardiac Disease (10:30AM - 11:00AM)

Speakers

Moderators

Session Summary:

This session explores the latest advancements in gene therapies targeting inherited cardiac conditions, with a focus on Hypertrophic Cardiomyopathy (HCM) and Arrhythmogenic Cardiomyopathy (ACM). The speakers will discuss therapies aimed at specific genetic mutations, including therapies targeting the MYBPC3 gene for HCM and the PKP2 gene for ACM. Following the presentations, a panel of experts will engage in a moderated discussion.

Session 2: Targeted Small Molecules for Channelopathies (1:00PM - 1:25PM)

Speakers

Moderators

Session Summary:

This session will discuss small molecule therapies designed to target specific channelopathies, which are disorders caused by dysfunctional ion channels. The focus will be on two approaches: the use of an SGK1 inhibitor in Long QT syndrome types 1, 2, and 3 and a CAMKII inhibitor aimed at treating catecholaminergic polymorphic ventricular tachycardia (CPVT). Following the presentations, a panel of experts will engage in a moderated discussion.

Session 3: Gene Therapies for Inherited Cardiac Disease (2:30PM - 3:15PM)

Speakers

Moderators

Session Summary:

This session will discuss approaches for treating catecholaminergic polymorphic ventricular tachycardia (CPVT), with a focus on therapies targeting the RYR-2 and CASQ-2 genes. Additionally, the session will highlight gene therapy efforts aimed at addressing arrhythmogenic cardiomyopathy, specifically targeting the PKP-2 gene. Following the presentations, a panel of experts will engage in a moderated discussion to further explore these therapies.

Session 4: Gene Editing (3:15PM - 3:45PM)

Speaker

Moderators

Session Summary:

This session will provide insights into gene editing techniques currently being developed in treating Transthyretin (ATTR)
Amyloidosis and Hereditary Angioedema. Although there will not focus on current therapies being developed in the realm of inherited cardiac conditions, this session will explore how these genome editing techniques could potentially be adapted to target specific genes responsible for cardiac disorders. This presentation will be followed by a moderated discussion with experts in the field, who will delve deeper into the challenges and possibilities regarding gene editing techniques.